GlycoMimetics, Inc.

232 articles with GlycoMimetics, Inc.

• GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

  4/23/2019

  Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapy

• GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359

  4/22/2019

  GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of a paper in Nature Cell Biology that describes how tumor cells engage specific stromal components, most notably E-selectin, for propagation and outgrowth.

• GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359

  4/12/2019

  GlycoMimetics, Inc. (NASDAQ: GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone

• GlycoMimetics to Present at Upcoming Investor Conferences

  4/4/2019

  GlycoMimetics, Inc. announced that senior management will present corporate updates at two upcoming investor conferences in April.

• 

  Women's History Month: Top Influential Women in Biopharma

  3/19/2019

  March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.

• GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019

  3/7/2019

  GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 39th Annual Health Care Conference in Boston, on Tuesday, March 12, 2019, at 9:20 a.m. ET.

• GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results

  3/6/2019

  Initiated first company-sponsored Phase 3 pivotal trial of uproleselan in relapsed/refractory acute myeloid leukemia (AML) at sites in U.S., Europe, Canada and Australia

• GlycoMimetics Announces Transition Plan for Board of Directors

  3/5/2019

  Current Board Member Tim Pearson to become Board Chair effective at the close of the company’s annual meeting on May 17, 2019

• GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019

  2/27/2019

  GlycoMimetics, Inc. announced that it will host a conference call and webcast to report its fourth quarter and fiscal year 2018 financial results on Wednesday, March 6, 2018, at 8:30 a.m. ET.

• GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates

  12/4/2018

  GlycoMimetics, Inc. shared at the 60th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company’s highly potent E-selectin antagonist that is bioavailable via subcutaneous administration, and GMI-1757, the company’s dual-function E-selectin/galectin-3 antagonist.

• GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting

  12/3/2018

  Data in relapsed/refractory and newly diagnosed acute myeloid leukemia (AML) patients underscore clinical opportunities across multiple outcomes measures and subgroups

• 

  Upcoming Highlights from the 60th Annual American Society of Hematology Meeting

  11/30/2018

  The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.

• GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018

  11/29/2018

  GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host and webcast an investor/analyst meeting and update at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, on December 3 at 6 a.m. PT.

• Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors

  11/28/2018

  Mr. Jackson served as Celator’s CEO and as a member of its Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc.

• GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

  11/19/2018

  Pivotal Trial to Evaluate Efficacy and Safety of Uproleselan in Patients with Advanced Acute Myeloid Leukemia (AML); Trial to Enroll 380 Patients at US and International Sites

• GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements

  11/2/2018

  Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment

• GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting

  11/1/2018

  New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy

• GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018

  10/26/2018

  GlycoMimetics, Inc. announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018, at 8:30 a.m. ET.

• GlycoMimetics to Present at Upcoming November 2018 Investor Conferences

  10/24/2018

  GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows

• GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)

  8/14/2018

  Issued patent expands global patent portfolio for GlycoMimetics’ late-stage drug candidate targeting treatment of broad spectrum of patients with acute myeloid leukemia